We are live on ! Find out more
VEA

Virtus ETF Advisers Portfolio holdings

AUM $215M
1-Year Est. Return 53.68%
This Fund
S&P 500
This Quarter Est. Return
+3.91%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$245M
AUM Growth
+$31M
Cap. Flow
+$33M
Cap. Flow %
13.48%
Top 10 Hldgs %
7.31%
Holding
511
New
57
Increased
251
Reduced
151
Closed
49

Top Buys

Rank Stock Value
1
JNK icon
State Street SPDR Bloomberg High Yield Bond ETF
JNK
+$1.9M
2
COIN icon
Coinbase
COIN
+$1.35M
3
DOCU
DocuSign
DOCU
+$1.32M
4
SPOT icon
Spotify
SPOT
+$1.28M
5
UAL icon
United Airlines
UAL
+$1.28M

Top Sells

Rank Stock Value
1
APP icon
Applovin
APP
+$1.14M
2
EXPE icon
Expedia Group
EXPE
+$1.04M
3
KKR icon
KKR & Co
KKR
+$976K
4
CME icon
CME Group
CME
+$974K
5
CPAY icon
Corpay
CPAY
+$948K

Sector Composition

Rank Sector Weight
1 Financials 29.48%
2 Technology 14.86%
3 Healthcare 14.81%
4 Industrials 11.61%
5 Consumer Discretionary 6.33%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AVBP icon
351
ArriVent BioPharma
AVBP
$1.4B
$73.2K 0.03%
+2,747
New +$78.9K
NAMS icon
352
NewAmsterdam Pharma
NAMS
$3.26B
$72.8K 0.03%
2,834
-1,904
-40% -$40.4K
NGNE icon
353
Neurogene
NGNE
$672M
$72.8K 0.03%
3,183
+989
+45% +$36.8K
APGE icon
354
Apogee Therapeutics
APGE
$10.1B
$72.7K 0.03%
1,604
-534
-25% -$27.2K
MRUS
355
DELISTED
Merus
MRUS
$72.2K 0.03%
1,716
+121
+8% +$5.81K
MLYS icon
356
Mineralys Therapeutics
MLYS
$2.32B
$71.9K 0.03%
5,842
-1,425
-20% -$18.6K
NUVB icon
357
Nuvation Bio
NUVB
$2.29B
$71.9K 0.03%
27,031
-3,790
-12% -$9.76K
PHVS icon
358
Pharvaris
PHVS
$2.28B
$71.7K 0.03%
3,738
-1,351
-27% -$27.8K
MLTX icon
359
MoonLake Immunotherapeutics
MLTX
$1.56B
$71.6K 0.03%
1,322
-840
-39% -$42.9K
PRTA icon
360
Prothena Corp
PRTA
$448M
$71.3K 0.03%
5,148
+833
+19% +$13.1K
NMRA icon
361
Neumora Therapeutics
NMRA
$306M
$71.2K 0.03%
6,720
-2,541
-27% -$30.5K
RCKT icon
362
Rocket Pharmaceuticals
RCKT
$343M
$71.1K 0.03%
5,656
+1,628
+40% +$24.5K
SMMT icon
363
Summit Therapeutics
SMMT
$10.2B
$71K 0.03%
3,979
-7,411
-65% -$144K
CGEM icon
364
Cullinan Oncology
CGEM
$1.06B
$71K 0.03%
5,828
+1,600
+38% +$23K
XERS icon
365
Xeris Biopharma Holdings
XERS
$1.45B
$70.9K 0.03%
+20,910
New +$67.3K
IDYA icon
366
IDEAYA Biosciences
IDYA
$3.43B
$70.9K 0.03%
2,758
+389
+16% +$11K
ETNB
367
DELISTED
89bio
ETNB
$70.8K 0.03%
9,056
-867
-9% -$7.14K
BLTE
368
Belite Bio
BLTE
$6.11B
$70.8K 0.03%
1,122
-721
-39% -$47.5K
TECX
369
Tectonic Therapeutic
TECX
$536M
$70.8K 0.03%
+1,533
New +$64.8K
CGON icon
370
CG Oncology
CGON
$6.1B
$70.6K 0.03%
2,463
-185
-7% -$6.33K
XENE icon
371
Xenon Pharmaceuticals
XENE
$6.1B
$70.6K 0.03%
1,802
-623
-26% -$25.8K
ABCL icon
372
AbCellera Biologics
ABCL
$1.65B
$70.6K 0.03%
24,099
-3,579
-13% -$9.97K
CNTA
373
DELISTED
Centessa Pharmaceuticals
CNTA
$70.6K 0.03%
4,214
-5,071
-55% -$84K
DFTX
374
Definium Therapeutics
DFTX
$5.6B
$70.5K 0.03%
+10,127
New +$69.7K
REPL icon
375
Replimune Group
REPL
$454M
$70.5K 0.03%
5,818
-3,921
-40% -$47.6K
13 14
15
16 17

Similar funds

NCM
NEXTBio Capital Management Menlo Park, California $215M AUM
SSA
SSA Swiss Advisors Zurich $216M AUM 17.86% 1-Year Est. Return
LIWM
Long Island Wealth Management Melville, New York $216M AUM 14.59% 1-Year Est. Return
VFG
V2 Financial group Naperville, Illinois $215M AUM 15.18% 1-Year Est. Return
IAM
Impala Asset Management Palm Beach, Florida $215M AUM 86.77% 1-Year Est. Return
1M
1248 Management Kansas City, Missouri $216M AUM 12.29% 1-Year Est. Return
GC
GatePass Capital Independence, Ohio $214M AUM 29.83% 1-Year Est. Return
RC
Roubaix Capital Denver, Colorado $214M AUM 32.43% 1-Year Est. Return

Virtus ETF Advisers's Q4 2024 Portfolio in Review

As of Q4 2024, Virtus ETF Advisers held 511 positions worth $245M, up 15% from $214M the previous quarter. Its ten largest holdings account for 7.3% of the portfolio.

Virtus ETF Advisers deployed $33M of net new capital in Q4 2024, opening 57 new positions and adding to 251 existing holdings. Its largest new stake was State Street SPDR Bloomberg High Yield Bond ETF: 19,660 shares worth $1.88M.

By sector, the portfolio is most concentrated in Financials at 29% of assets, up from 28% a quarter earlier, followed by Technology and Healthcare.

On the sell side, the largest reduction was Applovin, an estimated $1.14M trimmed.

  • Virtus ETF Advisers's largest Q4 2024 buy was State Street SPDR Bloomberg High Yield Bond ETF: 19,660 shares worth $1.88M.
  • Virtus ETF Advisers added most to Eagle Point Credit Company in Q4 2024, an estimated $515K increase.
  • Virtus ETF Advisers's biggest Q4 2024 reduction was Applovin, cutting an estimated $1.14M.
  • Virtus ETF Advisers fully exited Expedia Group in Q4 2024, selling an estimated $1.04M.
  • Virtus ETF Advisers's ten largest holdings make up 7.3% of its $245M portfolio in Q4 2024.
  • Virtus ETF Advisers opened 57 new positions and closed 49 in Q4 2024.
  • Virtus ETF Advisers's portfolio value rose 15% quarter-over-quarter to $245M.

Based on Virtus ETF Advisers's 13F filing for Q4 2024, filed 14 Feb 2025.